Journal of medicinal chemistryHumansAnimalsAntineoplastic AgentsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 9
Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability.
Yaoguang Huang, Lianyu Tang, Xiaoyu Shi, Wenwu Liu, Xupeng Yang, Mingyu Wang, Zifeng Guo, Wenjing Li, Xianduo Sun, Anhua Wang, Jingming Jia
Published: 202610.1021/acs.jmedchem.5c02206
Abstract
CDK4 and CDK9 are key kinases governing cell cycle progression and transcriptional regulation, respectively. Accumulating evidence supports the therapeutic potential of their concurrent inhibition in oncology. Screening of our in-house natural produc…
Preview only. Read the full abstract at the source